Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed the day trading at $53.69 up 3.81% from the previous closing price of $51.72. In other words, the price has increased by $+1.97 from its previous closing price. On the day, 743828 shares were traded.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $72.
Evercore ISI Upgraded its In-line to Outperform on June 06, 2023, whereas the target price for the stock was revised from $60 to $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 07 when KAKKIS EMIL D sold 30,000 shares for $45.00 per share. The transaction valued at 1,350,000 led to the insider holds 539,770 shares of the business.
KAKKIS EMIL D sold 30,000 shares of RARE for $1,436,100 on Dec 29. The President & CEO now owns 569,770 shares after completing the transaction at $47.87 per share. On Oct 23, another insider, Kassberg Thomas Richard, who serves as the CBO & EVP of the company, sold 39,878 shares for $32.78 each. As a result, the insider received 1,307,201 and left with 246,860 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4.42B and an Enterprise Value of 3.89B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.18 while its Price-to-Book (P/B) ratio in mrq is 16.05. Its current Enterprise Value per Revenue stands at 8.95 whereas that against EBITDA is -7.53.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is 46.87, while the 200-Day Moving Average is calculated to be 42.50.
Shares Statistics:
Over the past 3-months, RARE traded about 807.49K shares per day on average, while over the past 10 days, RARE traded about 757.18k shares per day. A total of 82.32M shares are outstanding, with a floating share count of 77.14M. Insiders hold about 6.31% of the company’s shares, while institutions hold 104.64% stake in the company. Shares short for RARE as of Feb 15, 2024 were 3.56M with a Short Ratio of 4.41, compared to 4.12M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.32% and a Short% of Float of 4.50%.
Earnings Estimates
Current recommendations for the stock of the company come from 16 analysts. On average, analysts expect EPS of -$1.76 for the current quarter, with a high estimate of -$1.39 and a low estimate of -$2.04, while EPS last year was -$2.33. The consensus estimate for the next quarter is -$1.63, with high estimates of -$1.36 and low estimates of -$2.01.
Analysts are recommending an EPS of between -$5.23 and -$8.12 for the fiscal current year, implying an average EPS of -$6.45. EPS for the following year is -$4.9, with 17 analysts recommending between -$1.58 and -$6.9.
Revenue Estimates
14 analysts predict $116.17M in revenue for the current quarter. It ranges from a high estimate of $124.6M to a low estimate of $98.8M. As of the current estimate, Ultragenyx Pharmaceutical Inc.’s year-ago sales were $100.5M, an estimated increase of 15.60% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $125.41M, an increase of 15.80% over than the figure of $15.60% in the same quarter last year. There is a high estimate of $130.1M for the next quarter, whereas the lowest estimate is $120.38M.
A total of 17 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $530.01M, while the lowest revenue estimate was $499.73M, resulting in an average revenue estimate of $513.09M. In the same quarter a year ago, actual revenue was $434.25M, up 18.20% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $649.05M in the next fiscal year. The high estimate is $920.7M and the low estimate is $541.73M. The average revenue growth estimate for next year is up 26.50% from the average revenue estimate for this year.
